Arcturus Therapeutics Holdings Inc (ARCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.09 is considered Undervalued compared with the five-year average of -8.01. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 10.05 to 18.42 according to relative valuation method. Compared to the current price of 8.35 USD , Arcturus Therapeutics Holdings Inc By Undervalued By 16.93%.

Relative Value

Fair Zone

10.05-18.42

Current Price：8.35

16.93%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Arcturus Therapeutics Holdings Inc (ARCT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Arcturus Therapeutics Holdings Inc (ARCT) has a current Price-to-Book (P/B) ratio of 0.76. Compared to its 3-year average P/B ratio of 2.19, the current P/B ratio is approximately -65.38% higher. Relative to its 5-year average P/B ratio of 2.55, the current P/B ratio is about -70.25% higher. Arcturus Therapeutics Holdings Inc (ARCT) has a Forward Free Cash Flow (FCF) yield of approximately -33.03%. Compared to its 3-year average FCF yield of -5.16%, the current FCF yield is approximately 539.78% lower. Relative to its 5-year average FCF yield of -10.79%, the current FCF yield is about 206.16% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ARCT competitors is 10.83, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT.O) exhibits a P/S ratio of 4.09, which is -62.29% above the industry average. Given its robust revenue growth of -58.84%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ARCT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ARCT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ARCT currently overvalued or undervalued?

Arcturus Therapeutics Holdings Inc (ARCT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.09 is considered Undervalued compared with the five-year average of -8.01. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 10.05 to 18.42 according to relative valuation method. Compared to the current price of 8.35 USD, Arcturus Therapeutics Holdings Inc is Undervalued By 16.93%.

What is Arcturus Therapeutics Holdings Inc (ARCT) fair value?

ARCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Arcturus Therapeutics Holdings Inc (ARCT) is between 10.05 to 18.42 according to relative valuation method.

How does ARCT's valuation metrics compare to the industry average?

The average P/S ratio for ARCT's competitors is 10.83, providing a benchmark for relative valuation. Arcturus Therapeutics Holdings Inc Corp (ARCT) exhibits a P/S ratio of 4.09, which is -62.29% above the industry average. Given its robust revenue growth of -58.84%, this premium appears unsustainable.

What is the current P/B ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Mar 03 2026?

As of Mar 03 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a P/B ratio of 0.76. This indicates that the market values ARCT at 0.76 times its book value.

What is the current FCF Yield for Arcturus Therapeutics Holdings Inc (ARCT) as of Mar 03 2026?

As of Mar 03 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a FCF Yield of -33.03%. This means that for every dollar of Arcturus Therapeutics Holdings Inc's market capitalization, the company generates -33.03 cents in free cash flow.

What is the current Forward P/E ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Mar 03 2026?

As of Mar 03 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a Forward P/E ratio of -2.48. This means the market is willing to pay $-2.48 for every dollar of Arcturus Therapeutics Holdings Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Arcturus Therapeutics Holdings Inc (ARCT) as of Mar 03 2026?

As of Mar 03 2026, Arcturus Therapeutics Holdings Inc (ARCT) has a Forward P/S ratio of 4.09. This means the market is valuing ARCT at $4.09 for every dollar of expected revenue over the next 12 months.

ARCT Valuation